CytomX Therapeutics (CTMX) PT Lowered to $8.50 at Citi
Citi analyst Mohit Bansal lowered the price target on CytomX Therapeutics (NASDAQ: CTMX) to $8.50 (from $11.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Lindt & Spruengli (LISN:SW) (LDSVF) PT Raised to CHF106,000 at UBS
- CLSA Upgrades a2 Milk Co (A2M:AU) (ACOPF) to Outperform (2)
- TCS Group Holding PLC (TCS:LI) PT Raised to $87 at JPMorgan
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!